Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial
Author(s):
Incrocci, L.; Wortel, R.C.; Alemayehu, W.G.; Aluwini, S.; Schimmel, E.; Krol, S.; Toorn, P.P. van der; Jager, H. de; Heemsbergen, W.; Heijmen, B.; Pos, F.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-08-31
Language
English
Is part of
The Lancet Oncology (2016), Vol. 17, no. 8, p. 1061-1069
